China Biotech Weekly

Briefings

Weekly intelligence on China biotech deals, CDE filings, and BIOSECURE compliance.

16 issues published · Every Thursday since December 2025

Showing 2 briefings tagged “Hengrui”

·9 min readFeatured

China Biotech Weekly #1: The ~$12B Signal — Why GSK-Hengrui Rewrites the Playbook

GSK-Hengrui's multi-asset deal valued at ~$12B reveals a new template for China out-licensing. Plus: 10 months to the BCC list, what CDE accepted this month, and the WuXi supply chain exposure that 34 US biotechs disclosed to the SEC.

GSKHengruiADCBIOSECUREdeal-analysis
·4 min read

China Biotech Weekly #1: $136B in 2025 — The Year Chinese Biotech Rewrote the Global Licensing Playbook

Chinese drug makers signed 157 out-licensing deals worth $136 billion in 2025 — nearly triple 2024. We break down the full-year numbers, the five mega-deals that defined the market, and what the data tells us about 2026.

LicensingADCBispecificAstraZenecaGSK

Get new briefings delivered

Every Thursday. Free. Unsubscribe anytime.